Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06596434 · ClinicalTrials.gov registry record · Phase 2

4-Aminopyridine to Treat Skin Burns

A Phase 2 study of Burns and Wounds and Injuries, sponsored by John Elfar.

Recruiting
Registry status
Phase 2
Development phase
200
Enrollment target
1
Study location

NCT06596434 is a Phase 2 study of Burns and Wounds and Injuries that is actively recruiting participants, run by John Elfar. The registered enrollment target is 200 participants, above the 78-participant average among 36 other Burns trials with a reported enrollment target (156% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06596434, a Phase 2 study of Burns and Wounds and Injuries, is actively recruiting participants, sponsored by John Elfar.

RECRUITING
Registry status
Phase 2
Development phase
200 participants
Enrollment target
1
Study location

Study Summary

Many patients suffer from traumatic burns and current treatments do not increase the regenerative potential of either skin grafts or the remaining uninjured skin. There is a need to develop treatments to accelerate and improve healing of burn injuries. More research is needed to evaluate the role of 4-AP, a promising new agent with an excellent safety profile, on wound and burn healing. The investigational treatment will be used to test the hypothesis that 4-AP accelerates burn healing in traumatically burned patients.

Interventions

  • OTHER Placebo
  • DRUG Drug: 4-Aminopyridine

Study Locations (1)

Arizona

  • University of Arizona - Tucson

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2026-01-01
Est. Completion 2028-09
Phase Phase 2

Sponsor

John Elfar

3 total trials

What the Registry Record Tells You About NCT06596434

The ClinicalTrials.gov registry entry for NCT06596434 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 78-participant average among 36 other Burns trials with a reported enrollment target (156% higher). The listed sponsor is John Elfar, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Burns appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06596434 reports 1 study location spanning 1 distinct geographic area - top geographies include Arizona.

Frequently Asked Questions

What is clinical trial NCT06596434 about?

NCT06596434 is a clinical study titled "4-Aminopyridine to Treat Skin Burns". Many patients suffer from traumatic burns and current treatments do not increase the regenerative potential of either skin grafts or the remaining uninjured skin. There is a need to develop treatments to accelerate and improve healing of burn injuries. More research is needed to evaluate the role of...

What is the current status of trial NCT06596434?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2026-01-01. Estimated completion is 2028-09.

What conditions does trial NCT06596434 study?

This clinical trial studies the following conditions: Burns, Wounds and Injuries, Second Degree Burn.

What interventions are being tested in trial NCT06596434?

The interventions under investigation include: Placebo (OTHER), Drug: 4-Aminopyridine (DRUG).

Who is sponsoring clinical trial NCT06596434?

This trial is sponsored by John Elfar, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06596434 being conducted?

This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Burns

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.